⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

January 1, 2006Frontiers in bioscienceOpen Access

Factor Xa inhibitors: new anti-thrombotic agents and their characteristics

View Full Paper

Ask AI

Bookmark

Share

Design

Review

Authors

MIMasahiro IekoSapporo Medical University

Discussion

Loading...

Member takes

Implication

Supports exploration of Factor Xa inhibitors versus UFH; leaves open routine adoption pending randomized confirmation.

Key Points

Key points are not available for this paper at this time.

Cite This Study

Masahiro Ieko (2006) studied this question.

synapsesocial.com/papers/6a8a63b40e1a8f7244fd7581 https://doi.org/10.2741/1794

Topics

Dual antiplatelet therapy Anticoagulation in AF

View Full Paper

Ask AI

Bookmark

Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Fondaparinux: an update on new study results2005 · 33 citations
2Use of Low-Molecular-Weight Heparins in the Management of Acute Coronary Artery Syndromes and Percutaneous Coronary Intervention2003 · 91 citations
3Low-molecular-weight heparinoid compared with warfarin for prophylaxis of deep-vein thrombosis in patients who are operated on for fracture of the hip. A prospective, randomized trial.1991 · 79 citations
4Thromboembolic prophylaxis in total hip replacement: A comparison between the low molecular weight heparinoid Lomoparan and heparindihydroergotamine1992 · 38 citations
5Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin2004 · 210 citations